BioSpace News Archive

InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will release its 2024 fiscal third quarter financial results on Tuesday, May 7, 2024, after market close.

BiomX Inc. today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024, which is being held from 27-30 April.

Tome Biosciences, Inc. today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD.

Prime Medicine, Inc. today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at the 3rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024); the American Society of Cell & Gene Therapy 27th Annual Meeting.

PROCEPT BioRobotics today announced that 12 abstracts highlighting its Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas, from May 3 - 6, 2024.

UNITY Biotechnology, Inc. today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been extended from 24 to 36 weeks to assess potentially greater durability compared to aflibercept.

University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test.

Edgewise Therapeutics, Inc. today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment of Duchenne muscular dystrophy (Duchenne).

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2024.

Palisade Bio, Inc. today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.